Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics, Inc. , a genomic medicine company, today announced that the American Society of Gene & Cell Therapy has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT Annual...
Kamy Pooler Greg Davis American Society Of Gene Cell Therapy Development Of Blood Head Of Research At Sangamo Development Of Modular Integrases Mints
Source: marketscreener.com